SeQuent® Please - The visionary way to treat vascular stenosis
B. Braun Vascular Systems presents the first Drug Eluting Balloon for PTCA, based on a polymer-free carrier matrix. This most innovative product is the result of our sustained research for new options and improvements in the field of coronary angioplasty. Clinically proven, it offers completely new procedural options to treat vascular stenoses since the drug elution does not require a stent platform.
patient information
Coronary artery disease and treatment options Within the following sites we would like to answer some of your questions on coronary artery disease (CAD), the diagnostic procedure and state of the art treatment options. more >>
latest news
Effective help against narrowing of coronary arteries The data of the PEPCAD II trial (Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease II) was recently officially published in the scientifically highly reputed journal CIRCULATION of the American Heart Association.
The PEPCAD II study confirms SeQuent® Please superiority in safety and clinical outcomes in comparison to a paclitaxel DES for patients with in-stent-restenosis. For more information, please find an abstract of the six-month angiographic PEPCAD II outcomes on www.circ.ahajournals.org
The above-mentioned product may not be registered in your country. Please check your local B. Braun website or contact your local B. Braun partner.
Contact
B. Braun Melsungen AG
Vascular Systems
Sieversufer 8
12359 Berlin
Germany
Tel. +49 30 68 98 97-0
Fax +49 30 68 98 97-30
E-Mail: vascular.systems@bbraun.com
Potential cost savings with innovative medical devices 2008
The Spectaris study analyses and demonstrates potential cost savings based on the example of selected innovative medical devices. The intention is to save costs combined with a more effective treatment. You will find the potential cost savings with SeQuent® Please on pages 48 to 51.
